
FORM D

Notice of Exempt Offering of Securities

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C.



1. Issuer's Identity		
CIK (Filer ID Number)	Previous Name(s) 🔲 None	Entity Type
0001173281	BBM HOLDINGS, INC.	Corporation
Name of Issuer	PRIME RESOURCE INC	C Limited Partnership
Ohr Pharmaceutical Inc		C Limited Liability Company
Jurisdiction of Incorporation/Organization	_	C General Partnership
DELAWARE]	C Business Trust
Year of Incorporation/Organizati	on	C Other
 Over Five Years Ago 		
• Within Last Five Years (Specify Year)		

C Yet to Be Formed

2. Principal Place of Business and Contact Information Name of Issuer Ohr Pharmaceutical Inc Street Address 1 Street Address 2

800 THIRD AVENUE		11TH FLOOR			
City	State/Province/Country	ZIP/Postal Code	Phone No. of Issuer		
NEW YORK	NEW YORK	10022	212-682-8452		

3. Related Persons

Last Name	First Name	Midd	le Name
Greenstein	Ira		
Street Address 1	Stre	et Address 2	
c/o Ohr Pharmaceutical, Inc.	80	0 Third Avenue, 11th	1 Floor
City	State/Province/Country	ZIP/P	ostal Code
New York	NEW YORK	1002	22
Relationship:	ive Officer	irector	Promoter

Clarification of Response (if Necessary)

Last Name	First Name	Middle Name
Taraporewala	Irach	
Street Address 1	Street Address 2	
c/o Ohr Pharmaceutical, Inc.	800 Third Avenu	ie, 11th Floor
City	State/Province/Country	ZIP/Postal Code
New York	NEW YORK	10022
Relationship: Execut	ive Officer Director	Promoter

Clarification of Response (if Necessary)

Last Name	First Name		Middle Name			
Hirschman Orin						
Street Address 1		Street Address 2				
c/o Ohr Pharmaceutical, Inc.		800 Third Aver	11th Floor	٦		
City	State/Province	Country	ZIP/Postal Code			
New York	NEW YORK	-	10022			
<u>[</u>						
Relationship:	ecutive Officer	Director	Promoter			
Clarification of Response (if Neces	ssary)					
Last Name	First Name		Middle Name	-		
Riedhammer	Thomas		٦			
Street Address 1		Street Address 2	-			
c/o Ohr Pharmaceutical, Inc.		800 Third Aver	11th Floor			
City	State/Province	/Country	ZIP/Postal Code			
New York	NEW YORK	-	10022			
[
Relationship:	ecutive Officer	Director	Promoter			
Clarification of Response (if Necessary)						
			Middle Name	_		
Last Name	First Name		Middle Name	-		
Last Name		Streef Address 2]	_		
Last Name Almenoff Street Address 1	First Name	Street Address 2]	_		
Last Name Almenoff Street Address 1 c/o Ohr Pharmaceutical, Inc.	First Name	800 Third Aver	nue, 11th Floor			
Last Name Almenoff Street Address 1 C/0 Ohr Pharmaceutical, Inc. City	First Name	800 Third Aver	nue, 11th Floor ZIP/Postal Code			
Last Name Almenoff Street Address 1 c/o Ohr Pharmaceutical, Inc.	First Name	800 Third Aver	nue, 11th Floor	_		
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York	First Name	800 Third Aver	nue, 11th Floor ZIP/Postal Code			
Last Name Almenoff Street Address 1 C/0 Ohr Pharmaceutical, Inc. City New York	First Name June State/Province NEW YORK ecutive Officer	/Country	nue, 11th Floor ZIP/Postal Code 10022	_		
Last Name Almenoff Street Address 1 C/0 Ohr Pharmaceutical, Inc. City New York Relationship:	First Name June State/Province NEW YORK ecutive Officer	/Country	nue, 11th Floor ZIP/Postal Code 10022	_		
Last Name Almenoff Street Address 1 C/0 Ohr Pharmaceutical, Inc. City New York Relationship:	First Name June State/Province NEW YORK ecutive Officer	/Country	nue, 11th Floor ZIP/Postal Code 10022			
Last Name Almenoff Street Address 1 C/0 Ohr Pharmaceutical, Inc. City New York Relationship:	First Name June State/Province NEW YORK ecutive Officer	/Country	nue, 11th Floor ZIP/Postal Code 10022	_ 		
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York Relationship: Ex Clarification of Response (if Neces	First Name June State/Province NEW YORK ecutive Officer sary)	/Country	nue, 11th Floor ZIP/Postal Code 1 10022 Promoter			
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York Relationship: Ex Clarification of Response (if Neces Last Name	First Name	/Country	nue, 11th Floor ZIP/Postal Code 1 10022 Promoter	_ 		
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York Relationship: Ex Clarification of Response (if Neces Last Name Backenroth	First Name	Country	nue, 11th Floor ZIP/Postal Code 1 10022 Promoter Middle Name	_ 		
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York Relationship: Ex Clarification of Response (if Neces Last Name Backenroth Street Address 1	First Name	Street Address 2	nue, 11th Floor ZIP/Postal Code 1 10022 Promoter Middle Name	<u>-</u>		
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York Relationship: Ex Clarification of Response (if Neces Last Name Backenroth Street Address 1 c/o Ohr Pharmaceutical, Inc.	First Name June State/Province NEW YORK ecutive Officer sary) First Name Sam	800 Third Aver /Country Director Street Address 2 800 Third Aver /Country	nue, 11th Floor ZIP/Postal Code 10022 Promoter Middle Name 1 Niddle Name 1 Niddle Name	- 		
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City Relationship: Ex Clarification of Response (if Neces Last Name Backenroth Street Address 1 C/o Ohr Pharmaceutical, Inc. City	First Name June State/Province First Name First Name State/Province	800 Third Aver /Country Director Street Address 2 800 Third Aver /Country	Iue, 11th Floor ZIP/Postal Code 10022 Promoter Middle Name Iue, 11th Floor ZIP/Postal Code			
Last Name Almenoff Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York Relationship: Ex Clarification of Response (if Neces Last Name Backenroth Street Address 1 C/o Ohr Pharmaceutical, Inc. City New York	First Name June State/Province First Name First Name State/Province	800 Third Aver /Country Director Street Address 2 800 Third Aver /Country	Iue, 11th Floor ZIP/Postal Code 10022 Promoter Middle Name Iue, 11th Floor ZIP/Postal Code			

C Agriculture

Banking & Financial Services

- C Commercial Banking
- C Insurance
- C Investing
- C Investment Banking
- C Pooled Investment Fund

Other Banking & Financial © Services

C Business Services

Energy

- C Coal Mining
- C Electric Utilities
- C Energy Conservation
- C Environmental Services
- C Oil & Gas
- C Other Energy

Health Care

- Biotechnology
- C Health Insurance
- C Hospitals & Physicians
- C Pharmaceuticals
- C Other Health Care
- C Manufacturing

Real Estate

C

- C Commercial
- C Construction
- C REITS & Finance
 - Residential
- C Other Real Estate

C Retailing

C Restaurants

- Technology
- i comology
- C Computers
- C Telecommunications
- C Other Technology

Travel

- C Airlines & Airports
- C Lodging & Conventions
- C Tourism & Travel Services
- C Other Travel

C Other

5. Issuer Size

Revenue Range

- No Revenues
- C \$1 \$1,000,000
- C \$1,000,001 \$5,000,000
- \$5,000,001 \$25,000,000
- C \$25,000,001 \$100,000,000
- Over \$100,000,000
- C Decline to Disclose
- C Not Applicable

- Aggregate Net Asset Value Range No Aggregate Net Asset Value
- C \$1 \$5,000,000
- C \$5,000,001 \$25,000,000
- C \$25,000,001 \$50,000,000
- C \$50,000,001 \$100,000,000
- Over \$100,000,000
- C Decline to Disclose
- C Not Applicable
- 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

	Rule 504(b)(1) (not (i), (ii) or (iii))	Rule 505
	Rule 504 (b)(1)(i)	Rule 506(b)
Π	Rule 504 (b)(1)(ii)	Rule 506(c)
	Rule 504 (b)(1)(iii)	Securities Act Section 4(a)(5)
		Investment Company Act Section 3(c)

7. Type of Filing

☑ New Notice Date of First Sale

2014-12-24

First Sale Yet to Occur

T Amendment

8. Duration of Offering

Does the Issuer intend this offering to last more than one year?

C Yes O No

9. Type(s) of Securities Offered (select all that apply)

Pooled Investment Fund Interests Equity

Tenant-in-Common Securities 🔲 Debt

Γ	Mineral Property Securities	Option, Warrant or Other Right to Acquire Another Security
	Security to be Acquired Upon	

	Exercise of Option, Warrant or Other Right to Acquire Security	Π	Other (describe)
--	--	---	------------------

10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
Clarification of Response (if Necessary)
11. Minimum Investment
Minimum investment accepted from any outside \$ USD USD
12. Sales Compensation
Recipient CRD Number 🔲 None
(Associated) Broker or Dealer I None (Associated) Broker or Dealer CRD None Number
Street Address 2
City State/Province/Country ZIP/Postal Code
State(s) of Solicitation All States

13. Offering and Sales Amounts

Total Offering Amount	\$ 50000 USD	Indefinite					
Total Amount Sold	\$ 50000 USD)					
Total Remaining to be Sold	\$ 0 USD	Indefinite					
	Clarification of Response (if Necessary)						
counsel in settlement	counsel in settlement of legal fees.						
14. Investors							
	ities in the offering have been or may as accredited investors,	y be sold to persons who					
	ch non-accredited investors who alre	eady have invested in the					

Regardless of whether securities in the offering have been or may be sold
to persons who do not qualify as accredited investors, enter the total
number of investors who already have invested in the offering:

15. Sales Commissions & Finders' Fees Expenses

Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

1

Sales Commissions \$	0	USD	🗖 Esti	mate
Finders' Fees \$	0	USD	🗖 Esti	mate
Clarification of Response (if Necessary))			
16. Use of Proceeds				
Provide the amount of the gross proceed any of the persons required to be named If the amount is unknown, provide an e	d as executive officers, di	rectors or prom	oters in respo	
Clarification of Response (if Necessary)				

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each Issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which the issuer maintains its principal place of business or any State in which the state in which the state in which the issuer maintains its principal place of business or any State in which the state in which the state is fled.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Ohr Pharmaceutical Inc	/s/ Sam Backenroth	Sam Backenroth	Chief Financial Officer	2014-12-29